This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Status:
Recruiting
Trial end date:
2022-11-22
Target enrollment:
Participant gender:
Summary
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with
carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
Phase III Study is to Evaluate the efficacy of AL3810 in combination with carboplatin plus
(+) etoposide in untreated participants with ES-SCLC.